Novel approaches in anaplastic thyroid cancer therapy. Oncologist 2014 Nov;19(11):1148-55
Date
09/28/2014Pubmed ID
25260367Pubmed Central ID
PMC4221369DOI
10.1634/theoncologist.2014-0182Scopus ID
2-s2.0-84908508724 (requires institutional sign-in at Scopus site) 45 CitationsAbstract
Anaplastic thyroid cancer (ATC), accounting for less than 2% of all thyroid cancer, is responsible for the majority of death from all thyroid malignancies and has a median survival of 6 months. The resistance of ATC to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression, contributes to the very poor prognosis of this malignancy. This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways. Lastly, novel approaches and agents involving the Notch1 pathway, nuclear factor κB, Trk-fused gene, cancer stem-like cells, mitochondrial mutation, and tumor immune microenvironment are discussed. With a better understanding of the biological process and treatment modality, the hope is to improve ATC outcome in the future.
Author List
Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S, Prolla TA, Chen HAuthor
Kun-Tai Hsu MD Assistant Professor in the Plastic Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorGenetic Therapy
Histone Deacetylase Inhibitors
Histone Deacetylases
Humans
Molecular Targeted Therapy
NF-kappa B
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-ret
Receptor, Notch1
Signal Transduction
Thyroid Carcinoma, Anaplastic
raf Kinases
ras Proteins
